• Gossamer stops enrollment on BTK inhibitor program, goes all in on PAH drug

    13 days ago - By San Diego Biotechnology

    Gossamer Bio is stopping enrollment on a Phase Ib/II trial of its BTK inhibitor in CNS lymphoma, it said in its annual report Friday morning. The San Diego-based biotech said, “??Based upon the benefit /...
    Read more ...